IL6 and neoplasm: Importantly, high baseline IL6 levels are associated with poorer outcomes, suggesting that Cediranib’s anti-angiogenic properties may help modulate IL6-related pathways, potentially enhancing therapeutic responses and addressing inflammation-driven tumor progression.